Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FINANCE ROUNDUP: VC Investment Not Hurt Yet By Biotech Stock Slump

This article was originally published in Scrip

Executive Summary

Neon Therapeutics launched its immunotherapy platform with $55m in Series A venture capital, exceeding recent investments in several other private therapeutics companies, including a diabetes drug developer on its fifth round of funding.

Advertisement

Related Content

Therachon Moves 'Academic Prototype' Towards Clinic
Finance Watch: Two New VC Funds Raise $500m; One New US IPO; And Galena's 'Strategic Review'
VC Roundup: Infectious Disease Startup Snags $150m And Former Biogen CEO Scangos
Advaxis Advances Personalized Cancer Vaccines With Eye On Manufacturing Time, Cost
Immuno-Oncology Data Drive Deal Dollars Higher
BIO: Biotech Funding Captured By Oncology
IPO Update: Intellia Launch Shows CRISPR Still Excites While Others Struggle

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC029973

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel